<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210727052000N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-09</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of acceptance and commitment therapy on fear of disease progression, anxiety sensitivity and quality of life in patients with breast cancer in stages 1, 2 and 3</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of Acceptance and Commitment Therapy on fear of progression and quality of life of breast cancer patients in 1 and 2 and 3 stages</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57764</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Other design features: In the present study, we have an intervention group and a control group that only the intervention group received acceptance and commitment-based treatment, and both of these groups receive comments before and after the intervention and 3 months after the intervention. Needless to say, treatment books will be given to both groups. The researcher suggests that at the end of the 3-month test, if the control group wishes, the intervention group treatment will be performed for them, Randomization description: In this study, in order to achieve an equal number of patients in the control group and the intervention group, the block randomization method will be used, each block will be 5 people, the reason for using this random allocation is to ensure the equal number of people in intervention and Control In this study, we will have two blocks of intervention and control, the size of each block will be 5 people. For proper blinding, random assignment of patients to groups, after patient selection, ie after interviewing patients by the researcher, for random assignment to groups, patient statistics will be given to the statistical consultant to randomly assign patients in groups. To take. EXCEL statistical software will be used for random allocation, Blinding description: The names of all patients will be given to the statistical consultant for randomization after initial selection and review of inclusion and exclusion criteria for assignment to intervention and control groups. Also, patients in both control and intervention groups will be given a treatment book after random assignment to the groups, and the control group will have all three follow-up periods as the intervention group, but only the intervention group will receive treatment based on acceptance and commitment. They will. Therefore, patients will be unaware of whether they will be in the intervention group or the control group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Fear of disease progression in patients with breast cancer in stages 1, 2 and 3.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 5 sessions of 90-minute group therapy based on acceptance and commitment, which was first proposed by Dr. Hayes. (Dr. Zenozian and Dr. Patterson, with the help of the Second Supervisor Research Team and Dr. Hayes' approval of the treatment process) developed the protocol. Protocol processes include: values, cognitive fault, acceptance. There will be only 5 patients in each treatment group. Patients will attend the treatment session only once a week. Between sessions, assignments appropriate to the content of the sessions are given to patients, and at the beginning of each session, homework is reviewed. Not to mention, in each session, after 30 minutes of work, patients will have a 15-minute rest, and in each session, patients will be given masks, alcohol, biscuits and fruit juice packed with flowers. Intervention 2: Control group: will only have treatment and follow-up books without receiving acceptance and commitment-based psychotherapy. However, after 3 months of follow-up, according to the ethical principles, the patients in the control group will benefit from the treatment of the intervention group if they wish. The treatment book contains a summary of the intervention, but without any practice or presence of the therapist and without any metaphor used in the treatment sessions. The contents of the book include processes: values, cognitive fault, acceptance.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Except for unnecessary information that the patient does not agree to publish, the rest of the information is shared after the person is not identified.

When:
Access starts 6 months after the results are published

To whom:
Once published in articles, it can be made available to academics or therapists.

Conditions:
The use of information in order to fill the research gap is allowed.

Where to obtain:
Fatemeh Hassani Alimolk
E-mail: fatima.hassani@yahoo.com

How to obtain:
After the articles are published, the data will be made available by the journal.
Of course, the data will be available 6 months after the results are published.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Hassani alimolk</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zanjan university of Medical sciences, Mahdavi street, Azadegan sector, Zanjan</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4513956111</zip>
        <telephone>+98 44 3566 1160</telephone>
        <email>fatima.hassani75@yahoo.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Hassani alimolk</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zanjan university of Medical sciences, Mahdavi street, Azadegan sector, Zanjan</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4513956111</zip>
        <telephone>+98 44 3566 1160</telephone>
        <email>fatima.hassani75@yahoo.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range 18 to 50 years
No tumor metastasis
Patients who have only had 1 to 3 sessions of chemotherapy or radiotherapy
Patients must either be from Zanjan or have been staying in a guest house for at least 2 months
To have Physically ability to attend sessions
No psychosis disorders and personality disorders
Haven't been in psychotherapy during the last month
Not using psychiatric drugs
No diagnosis of misue of alcohol or addictive substances
Patients' satisfaction and interest in participating in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patients' dissatisfaction with continuing treatment
Worsening of patients' mental or physical condition during treatment
Absence of more than one session of treatment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50.011</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of nipple and areola, right female breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 5 sessions of 90-minute group therapy based on acceptance and commitment, which was first proposed by Dr. Hayes. (Dr. Zenozian and Dr. Patterson, with the help of the Second Supervisor Research Team and Dr. Hayes' approval of the treatment process) developed the protocol. Protocol processes include: values, cognitive fault, acceptance. There will be only 5 patients in each treatment group. Patients will attend the treatment session only once a week. Between sessions, assignments appropriate to the content of the sessions are given to patients, and at the beginning of each session, homework is reviewed. Not to mention, in each session, after 30 minutes of work, patients will have a 15-minute rest, and in each session, patients will be given masks, alcohol, biscuits and fruit juice packed with flowers.</i_keyword>
      <i_keyword>Control group: will only have treatment and follow-up books without receiving acceptance and commitment-based psychotherapy. However, after 3 months of follow-up, according to the ethical principles, the patients in the control group will benefit from the treatment of the intervention group if they wish. The treatment book contains a summary of the intervention, but without any practice or presence of the therapist and without any metaphor used in the treatment sessions. The contents of the book include processes: values, cognitive fault, acceptance.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Score of fear of disease progression questionnaire. Timepoint: Filling in the fear questionnaire of disease progression before the intervention, after the intervention and 3 months after the intervention. Method of measurement: Dr. Hersbach's Fear of Progress Questionnaire.</prim_outcome>
      <prim_outcome>Quality of life questionnaire score for cancer patients. Timepoint: Filling out the quality of life questionnaire for cancer patients before the intervention, after the intervention, 3 months after the intervention. Method of measurement: Quality of life questionnaire for cancer patients.</prim_outcome>
      <prim_outcome>Anxiety sensitivity questionnaire score. Timepoint: Filling out the anxiety sensitivity questionnaire before the intervention, after the intervention, 3 months after the intervention. Method of measurement: Anxiety Sensitivity Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Scale of experimental avoidance subscale of Acceptance and Practice Questionnaire. Timepoint: Admission and practice questionnaire is completed before the intervention, after the intervention, 3 months after the intervention. Method of measurement: Bond's Admission and practice questionnaire.</sec_outcome>
      <sec_outcome>Psychological flexibility (acceptance and practice questionnaire score). Timepoint: Admission and practice questionnaire is filled out before the intervention, after the intervention and 3 months after the intervention. Method of measurement: Bond's Acceptance and practice questionnaire.</sec_outcome>
      <sec_outcome>Cognitive integration (Gilders Cognitive integration questionnaire score). Timepoint: The cognitive integration questionnaire is filled out before the intervention, after the intervention and 3 months after the intervention. Method of measurement: Gilders Cognitive Integration Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-24</approval_date>
        <contact_name>Ethics Committee of Zanjan University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti hospital, Ark gate, Zanjan city, Zanjan province Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
